Investors & Media

Latest Presentations

All Presentations

Sangamo Corporate Presentation

Mar 30, 2026

Sangamo Corporate Presentation 4.8 MB

Source ASGCT 2026

Zinc finger fusions and synthetic DNA donor engineering improve the performance of reprogrammed modular integrases at the TRAC locus

May 12, 2026

Zinc finger fusions and synthetic DNA donor engineering improve the performance of reprogrammed modular integrases at the TRAC locus 2.1 MB

Source ASGCT 2026

Single-cell characterization of ST-506, a BBB-penetrant epigenetic repressor of Prion protein expression, in the nonhuman primate brain

May 12, 2026

Single-cell characterization of ST-506, a BBB-penetrant epigenetic repressor of Prion protein expression, in the nonhuman primate brain 7.1 MB

Source ASGCT 2026

ST-503 nonclinical safety studies evaluating zinc finger repressors regulating the expression of the Nav1.7 gene for treatment of small fiber neuropathy

May 12, 2026

ST-503 nonclinical safety studies evaluating zinc finger repressors regulating the expression of the Nav1.7 gene for treatment of small fiber neuropathy 1.2 MB

Source WORLDSymposium 2026

Isaralgagene civaparvovec (ST-920) shows positive mean annualized eGFR slope in adults with Fabry disease: Topline results from the registrational Phase 1/2 STAAR gene therapy study and long-term follow-up study

Feb 05, 2026

Isaralgagene civaparvovec (ST-920) shows positive mean annualized eGFR slope in adults with Fabry disease: Topline results from the registrational Phase 1/2 STAAR gene therapy study and long-term follow-up study 744.3 KB

Source WORLDSymposium 2026

Isaralgagene civaparvovec (ST-920) shows stable cardiac function over one year in patients with Fabry disease: Results from the registrational Phase 1/2 STAAR gene therapy study

Feb 06, 2026

Isaralgagene civaparvovec (ST-920) shows stable cardiac function over one year in patients with Fabry disease: Results from the registrational Phase 1/2 STAAR gene therapy study 664.2 KB

Source WORLDSymposium 2026

Isaralgagene civaparvovec (ST-920) gene therapy for adults with Fabry disease: Pharmacology and immunogenicity outcomes from the Phase 1/2 STAAR study and ongoing long-term follow-up

Feb 06, 2026

Isaralgagene civaparvovec (ST-920) gene therapy for adults with Fabry disease: Pharmacology and immunogenicity outcomes from the Phase 1/2 STAAR study and ongoing long-term follow-up 1 MB

Source WORLDSymposium 2026

A combined fertility, embryofetal development, AAV integration and germline transmission risk study in mice with ST-920 (isaralgagene civaparvovec) for Fabry disease

Feb 06, 2026

A combined fertility, embryofetal development, AAV integration and germline transmission risk study in mice with ST-920 (isaralgagene civaparvovec) for Fabry disease 297.3 KB

Source Prion 2025 Conference

ST-506 mediates brainwide lowering of prion protein in nonhuman primates via a conserved blood-brain-barrier crossing mechanism, as a potential one-time treatment for prion disease

Nov 04, 2025

ST-506 mediates brainwide lowering of prion protein in nonhuman primates via a conserved blood-brain-barrier crossing mechanism, as a potential one-time treatment for prion disease 2.7 MB

Latest Presentations and Publications

Scientific Presentations
Scientific Publications

Latest Publications

All Presentations

Source Science Translational Medicine

Engineered zinc finger repressors induce a prolonged and selective repression of SCN9A in nociceptors of nonhuman primates

March 26, 2026

Engineered zinc finger repressors induce a prolonged and selective repression of SCN9A in nociceptors of nonhuman primates 4.7 MB

Reprogrammed Serine Integrases Enable Precise Integration of Synthetic DNA

September 10, 2025

Reprogrammed Serine Integrases Enable Precise Integration of Synthetic DNA

Zinc Finger Repressors mediate widespread PRNP lowering in the nonhuman primate brain and profoundly extend survival in prion disease mice

March 10, 2025

Zinc Finger Repressors mediate widespread PRNP lowering in the nonhuman primate…